MedTrace Logo

Comparison of Intralipid With SMOF Lipid Following HSCT

NCT06625372 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-16

No results posted yet for this study

Summary

The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study. Primary hypothesis is Patients receiving SMOF LIPID will have better grafts than patients receiving intralipid. Also, complications after surgery and malnutrition will be less in this group.

Conditions

Interventions

DIETARY_SUPPLEMENT

SMOF lipid

The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.

DIETARY_SUPPLEMENT

INTRALIPIDS

The Intralipid will be given to the patient as fat component of total parenteral nutrition.

Sponsors & Collaborators

  • Shahid Beheshti University

    lead OTHER

Principal Investigators

  • Zahra Vahdat Shariatpanahi, Professor · School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-12
Primary Completion
2025-08-31
Completion
2025-12-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06625372 on ClinicalTrials.gov